

**PHARMACOVIGILANCE UNIT, KMCHIHSR**

**Series 22**

**DRUG SAFETY ALERT**

**JUNE – 2024**

Indian Pharmacopoeia Commission (IPC) after the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

S.NO	SUSPECTED DRUG	INDICATIONS	ADVERSE DRUG REACTION
1	Acetazolamide	As an adjunct in the treatment of chronic open-angle glaucoma; secondary glaucoma; as part of preoperative treatment of acute-angle closure glaucoma.	Choroidal effusion or Choroidal detachment
2	Amlodipine	<ul style="list-style-type: none"> <li>To reduce fatal coronary heart disease and non-fatal myocardial infarction, and to reduce the risk of stroke.</li> <li>To reduce the risk of coronary revascularization procedures and the need for hospitalization due to angina in patients with coronary artery diseases</li> </ul>	Lichenoid Keratosis

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the Pharmacovigilance unit, KMCHIHSR via **Email ([pharmacovigilance@kmchihsr.edu.in](mailto:pharmacovigilance@kmchihsr.edu.in)) / Landline No (04226806808).**

**Click on the below link to find the list of Monthly Drug Safety Alerts from Mar 2016 to Till date: <https://www.ipc.gov.in/images/List of Drug Safety Alerts as on 28th June 2024.pdf>**